SG Americas Securities
RARE icon

SG Americas Securities’s Ultragenyx Pharmaceutical RARE Stock Holding History

SG Americas Securities’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
53,668
+13,281
+33% +$330K ﹤0.01% 1561
2026
Q1 		$846K Buy
40,387
+8,183
+25% +$184K ﹤0.01% 1876
2025
Q4 		$741K Sell
32,204
-93,225
-74% -$3.07M ﹤0.01% 2263
2025
Q3 		$3.77M Buy
+125,429
New +$3.76M 0.01% 622
2025
Q2 		– Sell
-237,573
Closed -$8.6M – 3471
2025
Q1 		$8.6M Buy
237,573
+227,908
+2,358% +$9.48M 0.03% 342
2024
Q4 		$407K Sell
9,665
-2,648
-22% -$131K ﹤0.01% 1521
2024
Q3 		$684K Sell
12,313
-3,585
-23% -$183K ﹤0.01% 1410
2024
Q2 		$653K Buy
+15,898
New +$679K ﹤0.01% 1536
2024
Q1 		– Sell
-9,199
Closed -$440K – 3355
2023
Q4 		$440K Sell
9,199
-2,957
-24% -$115K ﹤0.01% 1567
2023
Q3 		$433K Buy
12,156
+9,677
+390% +$383K 0.01% 1868
2023
Q2 		$114K Sell
2,479
-22,007
-90% -$1.02M ﹤0.01% 2047
2023
Q1 		$982K Buy
24,486
+659
+3% +$28.3K 0.01% 1149
2022
Q4 		$1.1M Sell
23,827
-10,976
-32% -$432K 0.01% 904
2022
Q3 		$1.44M Buy
34,803
+13,296
+62% +$683K 0.02% 779
2022
Q2 		$1.28M Buy
21,507
+2,905
+16% +$179K 0.01% 1087
2022
Q1 		$1.35M Buy
18,602
+16,793
+928% +$1.17M 0.01% 1210
2021
Q4 		$152K Sell
1,809
-185
-9% -$15.1K ﹤0.01% 2821
2021
Q3 		$180K Sell
1,994
-135,090
-99% -$12.2M ﹤0.01% 3296
2021
Q2 		$13.1M Buy
137,084
+123,767
+929% +$12.9M 0.06% 270
2021
Q1 		$1.52M Buy
13,317
+10,087
+312% +$1.37M 0.01% 1242
2020
Q4 		$447K Sell
3,230
-951
-23% -$113K ﹤0.01% 2057
2020
Q3 		$344K Buy
4,181
+164
+4% +$13.6K ﹤0.01% 1864
2020
Q2 		$314K Sell
4,017
-8,981
-69% -$594K ﹤0.01% 2487
2020
Q1 		$578K Sell
12,998
-2,153
-14% -$112K 0.01% 1728
2019
Q4 		$647K Sell
15,151
-4,310
-22% -$178K 0.01% 1572
2019
Q3 		$833K Buy
19,461
+12,627
+185% +$686K 0.01% 1520
2019
Q2 		$434K Sell
6,834
-174,403
-96% -$11.1M ﹤0.01% 1970
2019
Q1 		$12.6M Buy
181,237
+174,934
+2,775% +$9.99M 0.12% 180
2018
Q4 		$274K Buy
6,303
+4,803
+320% +$263K ﹤0.01% 2236
2018
Q3 		$115K Sell
1,500
-1,283
-46% -$104K ﹤0.01% 2818
2018
Q2 		$214K Sell
2,783
-652
-19% -$42.1K ﹤0.01% 2566
2018
Q1 		$175K Buy
3,435
+315
+10% +$15.9K ﹤0.01% 2517
2017
Q4 		$145K Buy
3,120
+191
+7% +$9.37K ﹤0.01% 2651
2017
Q3 		$156K Buy
+2,929
New +$174K ﹤0.01% 2811
2017
Q1 		– Sell
-12,520
Closed -$880K – 3519
2016
Q4 		$880K Buy
12,520
+1,499
+14% +$106K 0.01% 1374
2016
Q3 		$782K Buy
+11,021
New +$703K 0.01% 1360
2016
Q2 		– Sell
-5,990
Closed -$379K – 2913
2016
Q1 		$379K Buy
+5,990
New +$392K ﹤0.01% 1891
2015
Q4 		– Sell
-4,461
Closed -$430K – 2931
2015
Q3 		$430K Buy
4,461
+3,037
+213% +$348K ﹤0.01% 1109
2015
Q2 		$146K Sell
1,424
-2,545
-64% -$198K ﹤0.01% 2144
2015
Q1 		$246K Sell
3,969
-610
-13% -$33.9K ﹤0.01% 1784
2014
Q4 		$201K Buy
4,579
+2,149
+88% +$98.5K ﹤0.01% 2415
2014
Q3 		$138K Buy
+2,430
New +$122K ﹤0.01% 2203

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SG Americas Securities's RARE Position: Q2 2026 in Review

SG Americas Securities increased its Ultragenyx Pharmaceutical (RARE) stake by 33% in Q2 2026, buying an estimated $330K and bringing the position to 53,668 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

SG Americas Securities first reported a position in RARE in Q3 2014 and has held it in 42 quarters since. The position peaked at $13.1M in Q2 2021. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • SG Americas Securities held 53,668 shares of Ultragenyx Pharmaceutical worth $1.79M as of Q2 2026.
  • SG Americas Securities bought 13,281 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $330K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1561 holding.
  • SG Americas Securities first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 42 quarters since.
  • SG Americas Securities's Ultragenyx Pharmaceutical position peaked at $13.1M in Q2 2021.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.